Medical Developments International (MVP) announced that Mundipharma has acquired exclusive Australian distribution rights for the Penthrox methoxyflurane inhaler. Mundipharma already has the rights to market Penthrox in most of Europe.
Mundipharma Australia and New Zealand Managing Director Jane Orr, commented, “Options for pain relief are limited in many clinical settings, particularly GP procedure rooms, so we welcome the opportunity to help address this important clinical need. Mundipharma has provided medicines for the management of pain and worked collaboratively with healthcare professionals to provide education on pain management for more than 20 years in Australia, so Penthrox is an ideal fit for our business.”
MVP CEO John Sharman said, “This is an exciting deal for MVP because Mundipharma has a respected presence in the pain market with broad sales force coverage across Australia. This presence in the field is expected to lead to impressive sales growth in the short to medium term, particularly within General Practitioner and Hospital channels.”
MVP Chairman David Williams added, “Mundipharma Australia has valuable expertise in pain management products, an established local presence and will invest further in the marketing of Penthrox in Australia. This partnership with Mundipharma to increase access for clinicians and patients across Australia is important for obvious reasons, but also to show international distributors the upside that is possible with a strong sales force.”
Read the MVP press release.
